The investment will fund the Phase I/Ib study of CGX-926 for MC4R-deficient genetic obesity in healthy subjects and patients.

In a new study, researchers have identified a way to stop cells from dying, opening the door to developing treatments that slow the progression of neurodegenerative conditions like Parkinson’s disease ...

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in ...

The collaboration targets disease areas where conventional small molecule drug discovery has faced challenges.

Developing targeted small molecule quantitative workflows for clinical research presents many challenges to researchers. From determining the optimum methods needed to enhance selectivity and ...

IRVINGTON, VA, UNITED STATES, March 19, 2026 /EINPresswire.com/ — The Dermatology Education Foundation today announced the launch of the Access Granted(TM) Initiative, a compreh ...

Small Molecule Drug Development Core Facility (SMDD Core) has the automation equipment, libraries, and experienced personnel to support a wide range of assay ...

Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a ...